Related Experiment Video
Updated: Jul 6, 2026
09:32
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
CD38 at the junction between prognostic marker and therapeutic target.
Silvia Deaglio1, Semra Aydin, Tiziana Vaisitti
1Department of Genetics, Laboratory of Immunogenetics, Biology and Biochemistry and CeRMS, Via Santena 19, 10126 Torino, Italy. silvia.deaglio@unito.it
Trends in Molecular Medicine
|April 12, 2008
Summary
CD38 is a negative prognostic marker in chronic lymphocytic leukemia (CLL). Targeting CD38 may disrupt cancer cell growth and enhance chemotherapy effectiveness.
Area of Science:
- Biochemistry
- Immunology
- Oncology
Background:
- CD38 is an ectoenzyme crucial for transmembrane signaling and cell adhesion.
- CD38 serves as a disease marker for leukemias and myeloma.
- CD38 is a recognized negative prognostic marker in chronic lymphocytic leukemia (CLL).
Purpose of the Study:
- To investigate the role of CD38 in CLL cell growth and survival.
- To explore CD38's involvement in chemokine-mediated cell migration in CLL.
- To establish the rationale for targeting CD38 in novel CLL therapeutic strategies.
Main Methods:
- Analysis of CD38's role in signaling pathways within CLL cells.
- Investigating the interaction of CD38 with chemokine receptors.
- Evaluating the potential of CD38-blocking reagents in preclinical models.
Main Results:
- CD38 is integral to growth and survival signaling networks in CLL cells.
- CD38 influences CLL cell migration in concert with chemokines and their receptors.
- Blocking CD38 is hypothesized to interfere with cancer cell growth circuits.
Conclusions:
- CD38 is a key mediator of CLL cell proliferation and survival.
- Targeting CD38 presents a promising therapeutic avenue for CLL.
- CD38-targeted therapies could sensitize leukemic cells to conventional chemotherapy.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...